A new lawsuit is calling attention to an unusual move by drug maker Actavis PLC that the New York attorney general says is designed to preserve sales of a brandname medication for Alzheimers disease The state attorney generals office filed suit Monday against Dublinbased Actavis in federal court in New York seeking to block the companys publicly stated plan to stop selling Namenda tablets which are given twice daily The suit accuses Actavis of forcing patients to switch to a oncedaily formulation of the same drug
  